These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 34991563)

  • 1. Clinicopathological investigation of secretory carcinoma cases including a successful treatment outcome using entrectinib for high-grade transformation: a case report.
    Suzuki K; Harada H; Takeda M; Ohe C; Uemura Y; Kawahara A; Sawada S; Kanda A; Sengupta B; Iwai H
    BMC Med Genomics; 2022 Jan; 15(1):6. PubMed ID: 34991563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salivary Gland Secretory Carcinoma: Clinicopathologic and Genetic Characteristics of 215 Cases and Proposal for a Grading System.
    Baněčková M; Thompson LDR; Hyrcza MD; Vaněček T; Agaimy A; Laco J; Simpson RHW; Di Palma S; Stevens TM; Brcic L; Etebarian A; Dimnik K; Majewska H; Stárek I; O'Regan E; Salviato T; Helliwell T; Horáková M; Biernat W; Onyuma T; Michal M; Leivo I; Skalova A
    Am J Surg Pathol; 2023 Jun; 47(6):661-677. PubMed ID: 37070739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-TRK Immunohistochemistry Is Highly Correlated With NTRK3 Gene Rearrangements in Salivary Gland Tumors.
    Csanyi-Bastien M; Lanic MD; Beaussire L; Ferric S; François A; Meseure D; Jardin F; Wassef M; Ruminy P; Laé M
    Am J Surg Pathol; 2021 Nov; 45(11):1487-1498. PubMed ID: 33899788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salivary Secretory Carcinoma Harboring a Novel ALK Fusion: Expanding the Molecular Characterization of Carcinomas Beyond the ETV6 Gene.
    Sasaki E; Masago K; Fujita S; Suzuki H; Hanai N; Hosoda W
    Am J Surg Pathol; 2020 Jul; 44(7):962-969. PubMed ID: 32205481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanding the Molecular Spectrum of Secretory Carcinoma of Salivary Glands With a Novel VIM-RET Fusion.
    Skálová A; Banečkova M; Thompson LDR; Ptáková N; Stevens TM; Brcic L; Hyrcza M; Michal M; Simpson RHW; Santana T; Michal M; Vaněček T; Leivo I
    Am J Surg Pathol; 2020 Oct; 44(10):1295-1307. PubMed ID: 32675658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-Trk immunohistochemistry is a sensitive and specific ancillary tool for diagnosing secretory carcinoma of the salivary gland and detecting ETV6-NTRK3 fusion.
    Xu B; Haroon Al Rasheed MR; Antonescu CR; Alex D; Frosina D; Ghossein R; Jungbluth AA; Katabi N
    Histopathology; 2020 Feb; 76(3):375-382. PubMed ID: 31448442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using pan-TRK and RET Immunohistochemistry for the Detection of Fusion Types of Salivary Gland Secretory Carcinoma.
    Su YJ; Lee YH; Jin YT; Hsieh MS
    Appl Immunohistochem Mol Morphol; 2022 Apr; 30(4):264-272. PubMed ID: 35384876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-Trk immunohistochemistry reliably identifies ETV6-NTRK3 fusion in secretory carcinoma of the salivary gland.
    Bell D; Ferrarotto R; Liang L; Goepfert RP; Li J; Ning J; Broaddus R; Weber RS; El-Naggar AK
    Virchows Arch; 2020 Feb; 476(2):295-305. PubMed ID: 31423558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).
    Drilon A; Li G; Dogan S; Gounder M; Shen R; Arcila M; Wang L; Hyman DM; Hechtman J; Wei G; Cam NR; Christiansen J; Luo D; Maneval EC; Bauer T; Patel M; Liu SV; Ou SH; Farago A; Shaw A; Shoemaker RF; Lim J; Hornby Z; Multani P; Ladanyi M; Berger M; Katabi N; Ghossein R; Ho AL
    Ann Oncol; 2016 May; 27(5):920-6. PubMed ID: 26884591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secretory carcinoma of the sinonasal cavity and pharynx: A retrospective analysis of four cases and literature review.
    Yue C; Zhao X; Ma D; Piao Y
    Ann Diagn Pathol; 2022 Dec; 61():152052. PubMed ID: 36270241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pan-tropomyosin receptor kinase immunoreactivity, ETV6-NTRK3 fusion subtypes, and RET rearrangement in salivary secretory carcinoma.
    Yamamoto H; Nozaki Y; Sugii A; Taguchi K; Hongo T; Jiromaru R; Sato M; Nakano T; Hashimoto K; Fujiwara M; Oda Y
    Hum Pathol; 2021 Mar; 109():37-44. PubMed ID: 33301751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of mammaglobin immunohistochemistry as a proxy marker for the ETV6-NTRK3 translocation in the diagnosis of salivary mammary analogue secretory carcinoma.
    Bishop JA; Yonescu R; Batista D; Begum S; Eisele DW; Westra WH
    Hum Pathol; 2013 Oct; 44(10):1982-8. PubMed ID: 23773480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical/unbalanced ETV6/NTRK3 rearrangement in salivary secretory carcinoma with a focus on the incidence, the patterns, and the clinical implications.
    Sun J; Li J; Tian Z; Zhang C; Xia R; He Y
    J Oral Pathol Med; 2022 Sep; 51(8):721-729. PubMed ID: 36087274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mammary analog secretory carcinoma of the thyroid gland: A primary thyroid adenocarcinoma harboring ETV6-NTRK3 fusion.
    Dogan S; Wang L; Ptashkin RN; Dawson RR; Shah JP; Sherman EJ; Michael Tuttle R; Fagin JA; Klimstra DS; Katabi N; Ghossein RA
    Mod Pathol; 2016 Sep; 29(9):985-95. PubMed ID: 27282352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secretory Breast Carcinoma: A Histopathologic and Genomic Spectrum Characterized by a Joint Specific ETV6-NTRK3 Gene Fusion.
    Del Castillo M; Chibon F; Arnould L; Croce S; Ribeiro A; Perot G; Hostein I; Geha S; Bozon C; Garnier A; Lae M; Vincent-Salomon A; MacGrogan G
    Am J Surg Pathol; 2015 Nov; 39(11):1458-67. PubMed ID: 26291510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secretory Carcinoma with ETV6-NTRK3 Gene Fusion and Lymph Node Metastasis in Maxillary Gingiva: A Case Report with Pathological and Molecular Correlative Studies.
    Fujita J; Krishnan B; Green LK; Sandulache VC; Lai S
    Ann Clin Lab Sci; 2023 Sep; 53(5):800-805. PubMed ID: 37945013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological characteristics and outcome of 31 patients with ETV6-NTRK3 fusion gene confirmed (mammary analogue) secretory carcinoma of salivary glands.
    Boon E; Valstar MH; van der Graaf WTA; Bloemena E; Willems SM; Meeuwis CA; Slootweg PJ; Smit LA; Merkx MAW; Takes RP; Kaanders JHAM; Groenen PJTA; Flucke UE; van Herpen CML
    Oral Oncol; 2018 Jul; 82():29-33. PubMed ID: 29909898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammary Analogue Secretory Carcinoma of Salivary Glands: Molecular Analysis of 25 ETV6 Gene Rearranged Tumors With Lack of Detection of Classical ETV6-NTRK3 Fusion Transcript by Standard RT-PCR: Report of 4 Cases Harboring ETV6-X Gene Fusion.
    Skálová A; Vanecek T; Simpson RH; Laco J; Majewska H; Baneckova M; Steiner P; Michal M
    Am J Surg Pathol; 2016 Jan; 40(1):3-13. PubMed ID: 26492182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-grade salivary gland carcinoma with the ETV6-NTRK3 gene fusion: A case report and literature review of secretory carcinoma with high-grade transformation.
    Asai S; Sumiyoshi S; Yamada Y; Tateya I; Nagao T; Minamiguchi S; Haga H
    Pathol Int; 2021 Jun; 71(6):427-434. PubMed ID: 33848386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Profiling of Salivary Gland Intraductal Carcinoma Revealed a Subset of Tumors Harboring NCOA4-RET and Novel TRIM27-RET Fusions: A Report of 17 cases.
    Skálová A; Vanecek T; Uro-Coste E; Bishop JA; Weinreb I; Thompson LDR; de Sanctis S; Schiavo-Lena M; Laco J; Badoual C; Santana Conceiçao T; Ptáková N; Baněčkova M; Miesbauerová M; Michal M
    Am J Surg Pathol; 2018 Nov; 42(11):1445-1455. PubMed ID: 30045065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.